What happened
Donald Trump announced a tariff schedule for generic drug imports into the United States. Generic drug imports would keep zero tariffs for two years, then face a 100% tariff for one year and 200% thereafter if companies do not establish manufacturing in the United States by August 2028.
Indian pharmaceutical companies warned that such tariffs would raise costs for American consumers and would be hard for Indian firms to absorb because of dependence on global supply chains.
Why the issue matters
The proposal directly affects India’s pharmaceutical export sector and the affordability of medicines in the United States. It also shows how trade policy can be used to push manufacturing localisation, even when that can disrupt established cross-border supply chains.
Background and earlier position
Related current affairs
- Trump’s tariff threat on generics: What it could mean for Indian pharma firms
- Trump’s tariff threat on generics: Why it matters for Indian pharma firms
- Indian pharma sees little immediate threat from Trump’s 200% tariff plan
- Pharma push: Firms brace for tariff scenarios and cost impacts
- America’s tariff state is expanding. India must be patient
- Forced labour farce: India should not let the U.S.’s new tariffs push it towards a trade deal